CORALVILLE, Iowa, July 23, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) today released the following letter from management.
Management takes this opportunity to reiterate the Company's strategy. Vivakor's objective has always been to extend the quality and length of life through detection and prevention. All of its research objectives have been focused on technologies that can be commercialized that meet the Company's objectives. Vivakor's management and research teams evaluate each technology and its viability as a standalone product or as a joint venture technology. In doing so, management will make the decision to either procure any outside commercialization partners or to use company resources to take such technologies to market. Management's energies over the past year have been focused in this direction and will continue as such in order to create commercialization opportunities for Vivakor's technologies. This strategy has been necessary during this economic crisis as management tries to finance Vivakor's business model.
The Company has taken big strides forward toward commercialization of its technologies and is looking forward to the continued success of such efforts. During the past six months, management has been focused on the execution of key distribution agreements to commercialize its Vivathermic and Vivaceuticals technology. The distribution of Vivathermic vials domestically and internationally has taken significant efforts and we are pleased with the distributors that have seen the importance and the impact Vivathermic Vials will have on the biotech research industry. Such technologies aid in the detection and prevention of complex diseases that, when treated early, can extend the length and quality of an individual's life. Such efforts coincide with the Company's objectives.
About Vivakor, Inc.
Vivakor™ is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at www.vivakor.com.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.